Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Why Exact Sciences Stock Is Soaring 33% Today
Shares are rallying after a key new hire, and ahead of an investor conference.
http://finviz.com/quote.ashx?t=exas&ty=c&ta=1&p=d
What: After announcing recently that management hired a former Baird research analyst in a key role, and a day before presenting at William Blair's 36th annual growth stock conference, shares in Exact Sciences (NASDAQ:EXAS) surged 33% higher today.
So what: Exact Sciences shares are gaining ground, but today's rally follows a significant decline in the company's share price since the launch of Cologuard, the company's colon cancer screening test.
EXAS Chart
EXAS DATA BY YCHARTS.
The company didn't report any news today, but it did announce the appointment of Jeff Elliott to a senior role earlier this month, and management's calendar has been packed with investor conferences that could be factoring into the move higher.
Elliott, a former senior research analyst who covered the diagnostic and lab industries for Baird, is being tasked with identifying and pursuing strategic business opportunities for Exact Sciences, and while management didn't specifically say what opportunities Elliott will be evaluating, it could be that he's pursuing collaborations, licensing, or a business combination.
The company's Cologuard does very good job at screening for colon cancer, but winning reimbursement has been more challenging than expected, and despite a significant increase in screenings, spending continues to significantly outpace revenue. It's possible the hiring of Elliott signals that the C-suite is willing to entertain deals that could take some of the burden off of the company's balance sheet.
Exact Sciences has also been aggressively making its case with investors this month. On June 8, the company was at Goldman Sachs' 37th Annual Global Healthcare Conference, and on June 9, management presented at Jefferies Healthcare Conference. Tomorrow, CEO Kevin Conroy is scheduled to appear at William Blair's 36th Annual Growth Stock Conference in Chicago.
Now what: Sellers were holding 22% of the company's share float short entering today, and given today's move, it wouldn't be surprising if some sellers have decided to cover their positions ahead of tomorrow's presentation.
At this conference, management will probably reinforce the potential for a more than doubling in Cologuard tests and sales this year. Last year, the company completed 104,000 tests, and this year, management expects to complete more than 240,000 screenings. If Exact Sciences completes that many tests, it expects sales will reach at least $90 million, up from $39.4 million last year.
Overall, the potential to provide regular screenings to an increasingly larger and longer-living population of baby boomers has management pegging Cologuard's addressable market at $4 billion. That's undeniably a big market opportunity, but investors might want to temper some of their enthusiasm, because even if the company executes on its sales goals for 2016, it will still lose money. Total operating costs exited Q1 at an annualized $216 million.
Looks like a great day here. Have a good one all..
Flying PreMarket now $12+
The volume here is very very strong - this is not just a random pump. It could be another $EMES - I would actually buy and hold
* * $EXAS Video Chart 06-14-16 * *
Link to Video - click here to watch the technical chart video
EXAS -6% on tepid 1Q16 results: #msg-122374193.
EXAS presentation of "real-world" Cologuard data at AACR:
http://www.aacr.org/Newsroom/Pages/News-Release-Detail.aspx?ItemID=875#.VxZyKZMrJTY
FDA approves Epigenomics’ “Epi proColon” blood test for colorectal cancer: #msg-121884384
EXAS looks lot like these guys Genenews Ltd. (PC) (GNWSF)both in the same space yet GeneNews has a $10 million market cap and EXAS a $700 million market cap. Things that make you go hmmmm!!!!
EXAS reports 4Q15 results/2016 guidance:
http://finance.yahoo.com/news/exact-sciences-reports-fourth-quarter-110000544.html
Exact Sciences Corporation: Discounted Long or Attractive Short? http://marketexclusive.com/exact-sciences-corporation-nasdaqexas-discounted-long-or-attractive-short/3077/
A decent read found in my email today.
http://marketexclusive.com/exact-sciences-corporation-nasdaqexas-discounted-long-or-attractive-short/3077/
Wish the author had more than zero background in biotech. Not surprisingly, offers a real coin-flip opinion of the future.
EXAS -13% on soft 4Q15/unchanged 2016 guidance: #msg-119757011.
Medicare’s Cologuard reimbursement for 2016 will be $483 (a 2% reduction): #msg-118885476.
EXAS +4% on possibility of small reimbursement increase by Medicare (but it may be an error):
#msg-118782985
$EXAS recent news/filings
bearish 9.345
## source: finance.yahoo.com
Thu, 05 Nov 2015 18:04:19 GMT ~ EXACT SCIENCES CORP Financials
read full: http://finance.yahoo.com/q/is?s=exas
*********************************************************
Wed, 04 Nov 2015 13:17:16 GMT ~ Exact Sciences to Participate in November Investor Conferences
[at noodls] - MADISON, Wis.--(BUSINESS WIRE)-- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company will participate in two investor conferences during November. Kevin Conroy, the company's chairman ...
read full: http://www.noodls.com/view/EA8E40991233FD664B1521BED24AC7C9A20C88B4
*********************************************************
Wed, 04 Nov 2015 13:00:00 GMT ~ Exact Sciences to Participate in November Investor Conferences
[Business Wire] - Exact Sciences Corp. today announced that the company will participate in two investor conferences during November.
read full: http://finance.yahoo.com/news/exact-sciences-participate-november-investor-130000491.html
*********************************************************
Mon, 02 Nov 2015 21:32:10 GMT ~ Exact Sciences won't move HQ to downtown Madison, will expand in research park
read full: http://www.bizjournals.com/milwaukee/news/2015/11/02/exact-sciences-wont-move-to-downtown-madison-will.html?ana=yahoo
*********************************************************
Mon, 02 Nov 2015 20:36:02 GMT ~ Exact Sciences Aims to Collaborate with City of Madison & University of Wisconsin in Developing a Biotech Campus
[at noodls] - Madison-Based Manufacturer of Cologuard Focuses on a Scalable Environment that Expands Existing Footprint MADISON, Wis.--(BUSINESS WIRE)-- Exact Sciences Corp. (NASDAQ: EXAS) announced today that it will ...
read full: http://www.noodls.com/view/889A0F3B9A60EC9BE127FCC5BDF83FA17DAD1FB4
*********************************************************
$EXAS charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$EXAS company information
## source: otcmarkets.com
Operation timed out after 20000 milliseconds with 0 bytes received (28)
Array
(
[0] => Operation timed out after 20000 milliseconds with 0 bytes received (28)
)
$EXAS share structure
## source: otcmarkets.com
Market Value: $930,625,080 a/o Nov 19, 2015
Shares Outstanding: 96,338,000 a/o Oct 28, 2015
Float: Not Available
Authorized Shares: Not Available
Par Value: 0.01
$EXAS extra dd links
Company name: EXACT Sciences Corp.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/EXAS/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/EXAS/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=EXAS+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=EXAS+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=EXAS+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/EXAS/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/EXAS/news - http://finance.yahoo.com/q/h?s=EXAS+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/EXAS/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/EXAS/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/EXAS/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/EXAS/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/EXAS/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/EXAS/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/EXAS/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/EXAS/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=EXAS+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/EXAS
DTCC (dtcc.com): http://search2.dtcc.com/?q=EXACT+Sciences+Corp.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=EXACT+Sciences+Corp.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=EXACT+Sciences+Corp.&x=0&y=0
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/EXAS/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/EXAS
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/EXAS/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/EXAS/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/EXAS/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001124140&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/EXAS/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/EXAS/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/EXAS/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/EXAS/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=EXAS&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=EXAS
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/EXAS/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=EXAS+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=EXAS+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=EXAS
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=EXAS
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=EXAS+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/EXAS/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=EXAS+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/EXAS.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=EXAS
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/EXAS/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/EXAS/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/EXAS/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/EXAS/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/EXAS
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/EXAS
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/EXAS:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=EXAS
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=EXAS
$EXAS DD Notes ~ http://www.ddnotesmaker.com/EXAS
Here we go :)
Expectations? 15+ would be a wet dream
acts like it. would like to see a close over 9.30-9.40 level
This time through 10$? Decided to hold the biggest part of my shares for more. Looking great today again...
EXAS reports 3Q15 results: #msg-118128203.
Who might be able to give a secure answer...?!? Bottom in thats important to me. Maybe a 20-30% trading range from 7-9,50... Looks nice again today.
what is the short term target?
That was pure irony for me today. Have been on a trip to the states while my sell oder didn't hit at 10$ :(
a bid strange today - sell on good news? Shorts? We're at the very bottom right now imo - nice re entry
I was stuck on a plane at 9:30am and they didn't have WiFi. So mad I couldn't get out when it hit 9.93.
EXAS at 6.88
Back in with a starter position. What a wild ride today!
Thx. To you as well! Gonna add a person mark soon - not possible on my mobile app. Enjoy your day!
Looking good . Thank you for the info and reply. Best of luck
Always remember that last q's #'s need to be refered to a way higher pps. Nice days ahead here imo - reversal 'supported' by short coverage
Missed by a penny eps but beat revs I think that's good
Nice PR, strong close hod with big buys - looking good for a nice finish this week...
I think the cc tomorrow will be better than expected and the shorts are going to lose their shirts. Imo
That a good plan.
Time for some action on both - stock and board :)
Stable bottom, time for reversal
Lol it's so quiet. Not many updates on things
Actually, this board is much more active than it was before the bad news hit on Oct 5 (#msg-117494591).
This is a quiet board isn't it
right Klinsmann,
I wanted to sell in the premarket...but....
before next week bigger investment player are stepping in?
just a guess
Like a magnet - always back down to 8,20...
Stephens Inc upgraded EXAS to over-weight, 10/21/2015. Welcome upgrade transcending recent mischiefs!
That sounds good to me... TY
....next week can produce an explosive chartpicture back over 10 $
Let's see and wait
What is he overall consensus for the full reimbursement being rated A or B. Was this just a formality issue or something more. I hope some guidance will come out next Thursday on the issue. I was watching this stock years ago but it was given FDA approval and I missed that boat. I jumped on it the other day and hope things clear up. Thanks again
(NASDAQ:EXAS) dropped 46 percent and closed at $9.98, compared to the previous day's close of $18.53. The company plummeted after an unanticipated guideline from United States Preventative Services Task Force (USPSTF) that identified Cologuard, the company's colorectal cancer diagnostic product, as an "alternative" screening method, while leaving the product out of a group of recommended tests.
Talking about the guideline, Ro said, "We previously anticipated an A or B rating for Cologuard, which would have paved a clear path for full reimbursement coverage from private insurance companies." He added, "However, USPSTF did not offer a rating for Cologuard and instead categorized it as one of two ‘alternative' screening strategies. We now enter a 30-day public comment period and anticipate more clarity in the months thereafter."
Followers
|
60
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
637
|
Created
|
10/19/05
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |